{"id":"https://openalex.org/W7204683376","doi":"https://doi.org/10.1016/s2152-2650(26)02383-9","title":"MPN-1041: Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects","display_name":"MPN-1041: Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204683376","doi":"https://doi.org/10.1016/s2152-2650(26)02383-9"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)02383-9","doi":"https://doi.org/10.1016/s2152-2650(26)02383-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02383-9","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5148734166","display_name":"Sanjay Chanda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanjay Chanda","raw_affiliation_strings":["AN2 Therapeutics, Inc, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Menlo Park, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110084290","display_name":"Alex Smith","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Smith","raw_affiliation_strings":["AN2 Therapeutics, Inc, Consultant, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Consultant, San Francisco, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080609948","display_name":"George H. Talbot","orcid":"https://orcid.org/0000-0002-2868-2707","observed_orcids":["https://orcid.org/0000-0002-2868-2707"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George H Talbot","raw_affiliation_strings":["Talbot Advisors, Bradenton, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Talbot Advisors, Bradenton, FL, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S804","last_page":"S805"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":0.020999999716877937,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12286","display_name":"Erythrocyte Function and Pathophysiology","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erythropoiesis-suppression","display_name":"erythropoiesis inhibition","score":0.8159999847412109},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9129999876022339},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7860000133514404},{"id":"https://openalex.org/keywords/dose-ranging-study","display_name":"dose-ranging","score":0.5130000114440918},{"id":"https://openalex.org/keywords/hemoglobin-decline","display_name":"hemoglobin decrease","score":0.6320000290870667},{"id":"https://openalex.org/keywords/reticulocyte-count","display_name":"reticulocyte count","score":0.9589999914169312},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5870000123977661},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7129999995231628},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.625},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5329999923706055},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5960000157356262},{"id":"https://openalex.org/keywords/transaminase-elevation","display_name":"transaminase elevation","score":0.6480000019073486},{"id":"https://openalex.org/keywords/erythroid-cells","display_name":"erythroid cells","score":0.5090000033378601},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.3610000014305115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9771999716758728},{"id":"https://openalex.org/C2779703530","wikidata":"https://www.wikidata.org/wiki/Q837174","display_name":"Erythropoiesis","level":3,"score":0.682699978351593},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5950999855995178},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.38370001316070557},{"id":"https://openalex.org/C42407357","wikidata":"https://www.wikidata.org/wiki/Q521","display_name":"Physiology","level":1,"score":0.22750000655651093},{"id":"https://openalex.org/C2780844101","wikidata":"https://www.wikidata.org/wiki/Q2380264","display_name":"Ineffective erythropoiesis","level":4,"score":0.22429999709129333},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.21930000185966492},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.1979999989271164},{"id":"https://openalex.org/C2778534260","wikidata":"https://www.wikidata.org/wiki/Q218706","display_name":"Erythropoietin","level":2,"score":0.19529999792575836},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.1923000067472458}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)02383-9","doi":"https://doi.org/10.1016/s2152-2650(26)02383-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02383-9","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7204699716","https://openalex.org/W7204710797","https://openalex.org/W7204729953","https://openalex.org/W4311736702","https://openalex.org/W7204718928","https://openalex.org/W4401432430","https://openalex.org/W2422314213","https://openalex.org/W2043588000","https://openalex.org/W2409265112","https://openalex.org/W7204722226"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}